Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
Phase 1bOpen LabelREC-617+2 more
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT07633756
Phase 1
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main questi…
Advanced Urothelial CarcinomaOral Drug AdministrationOpen Label
Estimated
~$10 – $8,750
Flare Therapeutics Inc.NCT05929235